Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Oaktree Acquisition Corp. III Life Sciences Unit (OACCU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: OACCU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 4 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 4955 | Beta - | 52 Weeks Range 9.99 - 10.60 | Updated Date 04/24/2025 |
52 Weeks Range 9.99 - 10.60 | Updated Date 04/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Unit
Company Overview
History and Background
Oaktree Acquisition Corp. III Life Sciences Unit was a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Its existence was contingent on finding a suitable target within a specified timeframe.
Core Business Areas
Leadership and Structure
As a SPAC, leadership consisted of a management team experienced in investment and life sciences, overseen by a board of directors. Structure: standard SPAC formation with a management team searching for an acquisition target.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The SPAC operated within the life sciences sector, seeking to acquire a business within that industry. The life sciences industry is characterized by high growth potential, technological innovation, and regulatory scrutiny.
Positioning
As a SPAC, its positioning depended on finding a suitable acquisition target. It competed with other SPACs and traditional acquisition routes for promising life sciences companies.
Total Addressable Market (TAM)
The TAM was theoretically the entire value of the life sciences industry. Its positioning depended on the quality and scale of the target acquisition.
Upturn SWOT Analysis
Strengths
- Experienced management team in life sciences and investment
- Access to capital through public markets
- Flexibility to pursue various acquisition targets
Weaknesses
- Limited operating history
- Dependence on finding a suitable acquisition target
- Time constraints for completing an acquisition
- Potential for shareholder dilution
Opportunities
- Acquire a high-growth life sciences company
- Benefit from favorable industry trends
- Create value through operational improvements
- Capitalize on market inefficiencies
Threats
- Inability to find a suitable acquisition target
- Increased competition from other SPACs and acquirers
- Unfavorable market conditions
- Regulatory changes
Competitors and Market Share
Key Competitors
Competitive Landscape
The SPAC competed with other SPACs and traditional investors to acquire suitable life sciences companies. Competitive advantage depended on the SPAC's management team's expertise and network.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth was dependent on the performance of the acquired company.
Future Projections: Future projections dependent upon acquired company
Recent Initiatives: The only initiatives were those related to finding an acquisition target.
Summary
Oaktree Acquisition Corp. III Life Sciences Unit was a Special Purpose Acquisition Company, or SPAC, created with the intention of acquiring a company within the Life Sciences Industry. SPACs are inherently risky because their success is completely dependent on identifying and acquiring a valuable target. The primary risks were the inability to find a good target within the specified time window and competition with other SPACs. The success of such an entity hinges entirely on the expertise and deal-making ability of its management team.
Similar Companies
Sources and Disclaimers
Data Sources:
- SEC Filings for Oaktree Acquisition Corp. III Life Sciences Unit
- SPAC Research Websites
- Life Sciences Industry Reports
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Unit
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-10-24 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is headquartered in Los Angeles, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.